References
- WHO Essential Medicines. Library.At: http://mednet3.who.int/EMLib/DiseaseTreatments/MedicineDetails.aspx?MedIDName=443@mifepristone-misoprostol Accessed 27 August 2005.
- Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. National Evidence- Based Clinical Guidelines. London: RCOG, September 2004. Summary at: http://www.rcog.org.uk/resources/public/pdf/abortion_summary.pdf.Accessed 27 August 2005.
- Winikoff B. Global overview of medical abortion. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17–20 October 2004, Johannesburg.
- Clinical Guidelines: medical abortion 13–20 weeks. London: BPAS, 2005.
- UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. Methotrexate for the termination of early pregnancy: a toxicology review. Reproductive Health Matters 1997; 5 (9): 162–66.
- Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstetrics and Gynecology 2005;105(5/Pt 2): 1203–05.
- Ashok PW, Templeton A, Wagaarachchi PT, et al. Factorsaffecting the outcome of earlymedical abortion: a reviewof 4132consecutive cases. British Journalof Obstetrics and Gynaecology. 2002; 109 (11): 1281–89.
- World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems. Geneva7 WHO, 2003.
- von Hertzen H, Nguyen H, Piaggio G, et al. Comparison of two routes and two intervals of administration of misoprostol for the termination of early pregnancy: a randomised multicentre trial. Interim results (unpublished).
- Philip NM, Winikoff B, Moore K, et al. A consensus regimen for early abortion with misoprostol. International Journal of Gynecology and Obstetrics. 2004; 87: 281–83.
- Mifiprex (mifepristone) medication guide. At: www.fda.gov/cder/drug/infopage/mifepristone/medguide.htm. Accessed 15 June 2005.
- Hill NCW, et al. The placental transfer of mifepristone during the second trimester and its influence uponmaternal and fetal steroid concentrations. British Journal of Obstetrics and Gynaecology. 1990; 97: 406–11.
- Vogel D, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. American Journal of Obstetrics and Gynecology. 2004; 191: 2168–73.
- Hamoda H, Ashok PW, Flett G, et al. Medical abortion at 9–13 weeks’ gestation: a review of 1,076 consecutive cases. Contraception. 2005; 71: 327–32.
- Fiala C, Swahn ML, Stephansson O, et al. The effect of nonsteroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. Human Reproduction 2005;Aug 11 (Abstract only, e-publication).
- Shannon C, Brothers LP, Philip NM, et al. Infection after medical abortion: a review of the literature. Contraception. 2004; 70: 183–90.
- US Food and Drug Administration. FDA Alert for Healthcare Professionals: Mifepristone (marketed as Mifeprex), 22 July 2005. At: http://www.fda.gov/cder/drug/infosheets/hcp/mifepristonehcp.pdf and http://www.fda.gov/cder/drug/infopage/mifepristone/mifepristone-qa20050719.htm. Accessed 29 August 2005.